

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Myeloma

Third Guideline Development Group (GDG) meeting

13th June 2014

Board Room, NCC-C, Park House, Greyfriars Road, Cardiff

GROUP MEMBERSHIP & ACTION LIST

GDG Members	
Curly Morris (CM)	Monica Morris (MM)
Guy Pratt (GP)	Sam Ahmedzai (SA)
Matthew Jenner (MJ)	Nicola Montacute (NMo)
Matthew Streetly (MS)	Alan Chant (ACh)
Hamdi Sati (HS)	Andrea Guy (AG)
Nicola Mulholland (NM)	
NCC-C staff	
Angela Bennett (AB)	Kim Lewis (KL)
Nathan Bromham (NB)	Elise Hasler (EH)
Matthew Prettyjohns (MP)	Angharad Morgan (AM)
James Hawkins (JH)	
Apologies	
John Snowden (JS)	Lesley Roberts (LR)
Jane Woodward (JW)	Katie Perryman-Ford (KPF)

REPORTS OF DISCUSSIONS AT THE MEETING

1. Introductions

CM welcomed everyone to the 3rd meeting of the Myeloma GDG. Apologies were received from Katie Perryman-Ford, John Snowden, Lesley Roberts and Jane Woodward.

2. Declarations of Interest

The following declarations of interest were declared prior to the meeting:

- SA declared that he has received an honorarium and reimbursement of travel expenses from Mundipharma for lectures given during the Pain Forum lecture tour in South East Asia and Brazil on: 'pain in special populations'; assessing and treating pain in patients with substance abuse concerns'; the adequacy of opiod analgaesic consumption at country, global and regional levels and case presentations on cancer pain, neuropathic pain and non-malignant pain. The lecture tour took place between March and April 2014. This interest was categorised as personal pecuniary, specific meaning that SA must declare and withdraw from discussion of all guideline topics which include analgesics as interventions (Munipharma manufacture analgesics) until April 2015.
- SA declared that he has received reimbursement of travel and subsistence expenses to attend the European Hypnatraemia Network conference in Zurich from Otsuka in April 2014. This interest was categorised as personal pecuniary, non-specific meaning that SA can participate in discussion of all guideline topics as payment was not beyond reasonable amounts.

- SA declared that he gave a lecture on 'issues associated with therapeutic opioids – an evidence based approach to pain management at the World Institute of Pain in Maastricht in May 2014. Travel and subsistence expenses were reimbursed by Munipharma for attending and an honorarium from Mundipharma was paid to the University of Sheffield. This interest was categorised as non-personal pecuniary, non-specific meaning that SA can participate in discussion of all guideline topics as payment was not beyond reasonable amounts and pain management is not being investigated by the guideline.
- NM declared that she is principle investigator for a trial on biomarkers in lymphoma funded by the Elimination of Leukaemia Fund. This interest was categorised as non-personal pecuniary, non-specific meaning that NM can participate in discussion of all guideline topics as lymphoma is not being covered by the guideline and the research is not funded by the healthcare industry.
- NM declared that she is an investigator on a phase I/II study of ¹⁷⁷Lu-HH1 (Betalutin™) radioimmunotherapy for treatment of relapsed CD37+ non-Hodgkin's Lymphoma funded by Nordic Nanovector AS. This interest was categorised as non-personal pecuniary, non-specific meaning that NM can participate in discussion of all guideline topics as non-Hodgkin's Lymphoma is not being investigated by the guideline.
- NM declared that she is investigator on the NETTER-1 clinical trial. A phase III trial study comparing treatment with ¹⁷⁷Lu-DOTA0-Tyr3-Ostretate LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours funded by Advanced Accelerator Applications. This interest was categorised as non-personal pecuniary, non-specific meaning that NM can participate in discussion of all guideline topics as midgut carcinoid tumours are not being investigated by the guideline.
- NM declared that she is an investigator on the Foxfire study. An open label randomised phase III trial of 5-Fluorouracil, Oxaliplatin and Folinic acid +/- interventional radio-embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer. This interest was categorised as non-personal pecuniary, non-specific meaning that NM can participate in discussions of all guideline topics as colorectal cancer is not being investigated by the guideline.
- NM declared that she is in the process of applying for an ARSAC licence to be an investigator on a phase III, randomised double blind study of oral ixasomib citrate (MLN9708) maintenance therapy in patients with multiple myeloma following autologous stem cell transplant. Trial is funded by Millennium Pharmaceuticals. This interest was categorised as non-personal pecuniary, non-specific meaning that NM can participate in discussion of all guideline topics as maintenance therapy is not being investigated by the guideline.
- MS declared that he is being sponsored to attend the American Society of Haematology meeting in San Francisco in December 2014. Sponsorship is being paid by Janssen. This interest was classified as personal pecuniary, non-specific meaning that MS can participate in discussion of all guideline topics as payment was not beyond reasonable amounts.

The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

3. Discussions

The GDG discussed and finalised review protocols for topics C1, C2, D1, D2, E, F, G, H, I2, J, K, L3, M, N, O & P

The GDG discussed topics which were potential priorities for economic investigation. The GDG selected topics D1 & L3 for health economic investigation.

4. Close of meeting

CM thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Wednesday 23rd July 2014**, starting at 10.30 in the Board Room, NCC-C, Cardiff and closed the meeting.